Exclusive: Pfizer, Ginkgo sign R&D deal worth up to $331M to develop RNA drugs
In its latest Big Pharma deal, Ginkgo Bioworks will work with Pfizer to develop new RNA drugs, the Boston-based synthetic biology startup exclusively told Endpoints News.
The two aren’t disclosing many specifics about the collaboration, but the deal will focus on three RNA therapeutic programs, outlining $331 million in potential milestone payments, including an undisclosed amount upfront. Ginkgo CEO Jason Kelly said it’s the latest example of therapeutics being the fastest-growing area of Ginkgo’s business.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.